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1. Introduction 
Atopic Dermatitis (AD) is a common inflammatory itching skin disease1. This skin 
disorder affects a large number of children and adults2. Epidemiological studies show that 
up to 25% of children and up to 3% of adult are affected worldwide3. Several studies in 
addition suggest an increasing prevalence of AD. The clinical picture of AD is dominated 
by chronic eczematous skin lesions in typical localizations4. In infants and small children, 
the rash is often present on the skin around the knees and elbows and the cheeks5. In 
teenagers and adults, the rash is often present in the creases of the wrists, elbows, knees 
or ankles, and on the face or neck. Symptoms commonly could vary from person to 
person. The most common symptoms are dry, itchy skin and rashes on the face, inside the 
elbows and behind the knees, and on the hands and feet6. Itching is the most relevant and 
common symptom of atopic dermatitis. Scratching and rubbing in response to itching 
irritates the skin, increases inflammation, and actually increases itchiness. Itching is a 
particular problem during sleep when conscious control of scratching is lost. The 
appearance of the skin that is affected by atopic dermatitis depends on the amount of 
scratching and the presence of secondary skin infections. The skin may be red and scaly, 
be thick and leathery, contain small raised bumps, or leak fluid and become crusty and 
infected. These features can also be found in people who do not have atopic dermatitis or 
who have other types of skin disorders. Atopic dermatitis may also affect the skin around 
the eyes, the eyelids, and the eyebrows and lashes. Scratching and rubbing the eye area 
can cause the skin to redden and swell. Some people with atopic dermatitis develop an 
extra fold of skin under their eyes. Patchy loss of eyebrows and eyelashes may also result 
from scratching or rubbing. In addition clinically unaffected skin in AD is not normal. It is 
frequently dry and has a greater irritant skin response than normal healthy skin7. 
Microscopic studies reveal a sparse perivascular T-cell infiltrate in unaffected AD skin 
that is not seen in normal healthy skin8.  
There is a marked infiltration of CD41 activated memory T cells in acute AD9. Antigen-
presenting cells (eg, Langerhans cells inflammatory dendritic epidermal cells and 
macrophages) in lesional and, to a lesser extent, in nonlesional skin bear IgE molecules10. 
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Mast cell degranulation can be observed. Macrophages dominate the dermal mononuclear 
cell infiltrate. Eosinophils also contribute to the inflammatory response, and T cells remain 
present, although in smaller numbers than seen in acute AD11. Chronic AD skin lesions 
undergo tissue remodeling caused by chronic inflammation. These skin lesions are 
associated with thickened plaques with increased skin markings (lichenification), increased 
collagen deposition in the dermis, and dry fibrotic papules12. AD is characterized by dry 
skin, even involving nonlesional skin and increased transepidermal water loss13. In 
particular, ceramides serve as the major water-retaining molecules in the extracellular space 
of the cornified envelope, and the barrier function of these complex structures is provided 
by a matrix of structural proteins, which are bound to ceramides14. A reduced content of 
ceramides has been reported in the cornified envelope of both lesional and nonlesional skin 
in patients with AD. Changes in stratum corneum pH levels have been found in patients 
with AD and might impair lipid metabolism in the skin. Overexpression of stratum 
corneum chymotryptic enzyme is also likely to contribute to the breakdown of the AD 
epidermal barrier15. 
Atopic dermatitis is very common: it affects males and females and accounts for 10 to 20 
percent of all visits to dermatologists16. Although atopic dermatitis may occur at any age, it 
most often begins in infancy and childhood. Scientists estimate that 65 percent of patients 
develop symptoms in the first year of life, and 90 percent develop symptoms before the age 
of 517. The cause of atopic dermatitis is not known, but the disease seems to result from a 
combination of genetic and environmental factors18. Children are more likely to develop this 
disorder if one or both parents have had it or have had other  allergic conditions like asthma 
or allergic rhinitis19. While some people outgrow skin symptoms, approximately three-
fourths of children with atopic dermatitis go on to develop hay fever or asthma20. 
Environmental factors can bring on symptoms of atopic dermatitis at any time in 
individuals who have inherited the atopic disease trait21. 
2. Atopic dermatitis and immune system: AD as an allergic disease 
Atopic dermatitis is associated with malfunction of the body's immune system: the system 
that recognizes and helps fight bacteria and viruses that invade the body22. Scientists have 
found that people with atopic dermatitis have a low level of Interferon gamma (INF-γ) a 
cytokine (a protein) that is essential to the healthy function of the body's immune system 
and a high level of other cytokines such as IL-4 and IL-5 and IL-13 that lead to allergic 
reactions. The immune system can become misguided and create inflammation in the skin 
even in the absence of a major infection23. This can be viewed as a form of autoimmunity, 
where a body reacts against its own tissues. AD is also an important component of the 
atopic diathesis. AD frequently is associated with allergic respiratory disease and often is 
the first manifestation of allergic disease24. Patients suffering from AD will develop allergic 
rhinitis and asthma. The onset of AD generally occurs during the first 6 months of life. In 
adults with AD only 17% had onset after adolescence25. AD may arise from disregulation of 
IgE and T cell mediated hypersensitivity reactions26. Atopy is significantly associated with 
manifestation and severity of AD, especially in children. Exposure to aeroallergen (mites 
and pollen) has been shown to increase the risk factors for AD and AD severity27. Children 
with AD are at a high risk of allergic asthma and allergic rhinitis. Furthermore, 
aeroallergens are a trigger for exacerbations in adult AD. In about 80% of adult patients with 
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AD, the disease is associated with increased serum IgE levels, sensitization against 
aeroallergens and concomitant allergic rhinitis and asthma. Patients with AD can have very 
high serum IgE levels, often more than 10,000 IU/mL. It is important to note that specific 
IgE against allergens, whether measured in vivo by using SPTs or by using in vitro assays, 
does not equate to clinical disease or define clinical relevance in a given patient. In general, 
properly done SPTs to food allergens have a high negative predictive value, but the positive 
predictive value is only slightly higher than 50% for all patients. The inflammatory process 
in the skin initiates with the allergen uptake by epidermal dendritic cells which share in 
their surface the IgE-receptor. These cells, after the contact with the allergens, start the 
homing process of T cells. This process plays a central role for the inflammatory damage of 
skin28. Up to 80% of patients suffering from AD are sensitised against different aero and 
food allergens. This sensitisation is reflected by an increased total and allergen-specific IgE 
and/or by a positive Skin prick test29. 
2.1 AD as an allergic disease: The role of allergens sensitization 
Sensitization to inhalant allergens is often seen in patients with AD30. Allergens can 
exacerbate AD either by means of inhalation, direct contact with the skin, or ingestion. 
Sensitization can be detected by means of SPTs (if the skin is free from eczema) or by 
measurement of specific IgE antibodies. In addition, Atopy Patch Test can be used to 
assess the response in the skin. Most important allergens include dust mite, animal 
dander, and pollen confirmed by clinical trials and avoidance measures31. The role of dust 
mite allergen exposure is supported by patch tests, avoidance studies, and the very high 
titers of IgE antibodies to mite proteins in a large proportion of adults, as well as children 
older than 7 years with AD. The positive effect of house dust mite avoidance with special 
encasings has been shown in various studies32. Allergen avoidance however has limited 
efficacy in HMD allergic patients. 
2.2 Traditional therapeutic approach of AD 
Basic therapy of AD should comprise optimal skin care, addressing the skin barrier defect 
with the regular use of moisturizing and emollient topical products and skin hydration33. 
An additional relevant therapeutic approach is the identification and the avoidance of both  
specific and nonspecific trigger factors. Non specific irritants include clothing made from 
occluding or irritating synthetic or wool material. A key feature of AD is severe dryness of 
the skin caused by a dysfunction of the skin barrier with increased transepidermal water 
loss. This is typically accompanied by intense itch and inflammation. The regular use of 
emollients is important for addressing this problem, and together with skin hydration, it 
represents the mainstay of the general management of AD34. Emollients should be applied 
continuously, even if no actual inflammatory skin lesions are obvious. Corticosteroid creams 
and ointments have been used for many years to treat atopic dermatitis and other 
autoimmune diseases affecting the skin35. Sometimes over-the-counter preparations are 
used, but in many cases the doctor will prescribe a stronger corticosteroid cream or 
ointment. The side effects of uncontrolled topical steroid use, particularly on delicate skin 
areas, are well documented, and therefore topical steroid preparations should be applied no 
more than twice daily as short-term therapy for acute eczematous lesions36. Only mild to 
moderately potent preparations should be used on genital, facial, or intertriginous skin 
areas. New medications known as immuno modulators have been developed that help control 
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inflammation and reduce immune system reactions when applied to the skin. Examples of 
these medications are tacrolimus ointment and pimecrolimus cream37. They can be used in 
patients older than 2 years of age and have few side effects (burning or itching the first few 
days of application). They not only reduce flares, but also maintain skin texture and reduce 
the need for long-term use of corticosteroids. However corticosteroids and 
immunomodulators are not eziologic treatments of AD. These approaches in fact are mostly 
limited to control symptoms and suppress inflammatory reactions but they are not causal 
treatments of this skin condition. 
2.3 Thinking AD treatment approach differently: The specific allergen immunotherapy 
as an option 
Several anecdotal and case reports suggest clinical benefit from allergen-specific 
desensitization (specific immunotherapy [SIT]) in AD38. SIT is effective in the 
management of allergic asthma, allergic rhinitis/conjunctivitis, and stinging insect 
hypersensitivity39. There is some evidence it might be effective in the treatment of atopic 
dermatitis in patients with aeroallergen sensitivity. At least 12 placebo controlled trials 
have been conducted to evaluate the efficacy of SIT in AD patients40. A total of 9 trials 
(75%) reported significant positive effect of SIT in comparison with placebo. More 
recently, one double-blind controlled trial in children with dust mite allergy and AD 
failed to show efficacy of SIT compared with placebo after 8 months of therapy41. 
However, treatment for an additional 6 months resulted in clinical improvement, 
suggesting that prolonged desensitization might be more effective than placebo. A more 
recent multicenter, randomized, blinded, dose-response trial with house dust mite SIT in 
89 adults with chronic AD sensitized to dust mite showed that the SCORAD score 
decreased in the 3 dose groups in a dose-dependent manner and was significantly lower 
in the 2 high-dose groups compared with the low-dose group after 1 year of SIT42. The use 
of topical corticosteroids was also significantly reduced with higher doses, suggesting that 
SIT might be useful for patients with AD sensitized to house dust mite. This study 
demonstrated that adult atopic patients with severe form of AD could benefit from SIT. 
Children with AD with or without respiratory allergies or asthma have also been treated 
with allergen-specific oral desensitization (SLIT), with 69% of the group without 
respiratory allergies-asthma versus 74% of the group with respiratory allergies-asthma 
showing complete resolution of their skin disease after 24 months of therapy. To date, 
specific immunotherapy (SIT) is not an established therapeutic approach for the treatment 
of AD even if the recent Immunotherapy Practice Parameter states that AD could be a 
clinical indication for SIT. Some controlled trials have failed to show clinical efficacy of 
SIT in the treatment of AD. However, SIT with house dust mite (HDM) subcutaneous 
preparation has been recently shown, in a randomized double-blind trial, to improve 
eczema in patients with AD. 
2.4 Clinical efficacy of sublingual immunotherapy in AD 
In comparison with subcutaneous SIT, sublingual immunotherapy (SLIT) is considered a 
more convenient and safer approach for the treatment of some forms of allergies. So far, 
there is few and conflicting data regarding the efficacy and safety of Specific Sublingual 
Immunotherapy (SLIT) in patients with AD. In a randomised double blind trial a total of 
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56 children with AD were treated with SLIT HDM allergen extracts or the corresponding 
placebo for 18 months. Significant improvement of SCORAD (Scoring Atopic Dermatitis) 
in the active group was observed as soon as 9 months of treatment. Lower use of rescue 
medication in the active group was observed after 18 months43. We have conducted a 
multicenter trial evaluating the efficacy of SLIT in 96 AD patients showing that this 
therapeutic option is efficacious and safe44. More in details, 96 subjects (58 women and 38 
men; between 18 and 60 years of age) with AD and IgE-proved HDM sensitivity (Class 
>2) were enrolled in the trial after their informed consent. Exclusion criteria were severe 
asthma and treatment with systemic or high potent topical corticosteroids or 
immunosuppressant agents. Patients were treated with SLIT for at least 12 months. 
SCORAD was evaluated at baseline and after 12 months of treatment. Results: baseline 
SCORAD value (mean±SD) was 43.3±13.7 (range: 18-84). After 1 year of SLIT, SCORAD 
value was reduced to 23.7±13.3 (range: 0-65; p=0.0001; unpaired T-Test vs baseline). This 
was a 46% reduction in SCORAD in comparison with baseline time. A significant 
improvement, defined as a SCORAD reduction of >30%, was observed in 57 out of 96 
patients (59.2%). In 6 patients (5.9%) the SCORAD value did not change at the end of the 
observation period. In 33 patients (34.9%) the SCORAD reduction after SLIT was ≤30% in 
comparison with baseline (Figure 1). Specific-IgE serum levels were significantly  
 
 
Fig. 1. Evolution of SCORAD index at baseline and after1 year of SLIT treatment (n = 96); (p 
= 0.0001 paired t-test) 
(p=0.001) reduced after SLIT (Figure 2). No severe adverse events were observed during 
the trial. In this trial the SLIT with HDM extracts in patients with mild-moderate AD was 
effective in reducing the SCORAD after 1 year of SLIT treatment. In addition, the 
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treatment was very well tolerated. Treatment with SLIT, furthermore, has allowed a 
gradual and relevant reduction of concomitant therapies with corticosteroids and 
immunosuppressants. SLIT can modulate the immuno-system in patients with AD and 
HDM sensitivity. In conclusion the data available from different trials suggest that SIT 
(both SCIT and SLIT) could be a relevant therapeutic option in the management of AD. 
 
 
Fig. 2. Modification of specific anti HDM IgE serum levels at baseline and after1 year of SLIT 
treatment (n = 96); p = 0.0001 paired t-test. 
3. Conclusion 
Atopic Dermatitis (AD) is a common inflammatory itching skin disease affectings a large 
number of children and adults. Symptoms commonly could vary from person to person. 
The most common symptoms are dry, itchy skin and rashes on the face, inside the elbows 
and behind the knees, and on the hands and feet. Itching is the most relevant and 
common symptom of atopic dermatitis. Scratching and rubbing in response to itching 
irritates the skin, increases inflammation, and actually increases itchiness. The cause of 
atopic dermatitis is not known, but the disease seems to result from a combination of 
genetic and environmental factors. Children are more likely to develop this disorder if 
one or both parents have had it or have had other allergic conditions like asthma or 
allergic rhinitis. While some people outgrow skin symptoms, approximately three-fourths 
of children with atopic dermatitis go on to develop hay fever or asthma. AD frequently is 
associated with allergic respiratory disease and often is the first manifestation of allergic 
disease. Patients suffering from AD will develop allergic rhinitis and asthma. The 
inflammatory process  in the skin of patients with AD initiates with the allergen uptake by 
epidermal dendritic cells which share in their surface the IgE-receptor. These cells, after 
the contact with the allergens, start the homing process of T cells. This process plays a 
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central role for the inflammatory damage of skin. Up to 80% of patients suffering from AD 
are sensitised against different aero and food allergens. This sensitisation is reflected by 
an increased total and allergen-specific IgE and/or by a positive Skin prick test. So far not 
causative treatments are available for the treatment of AD. Topical corticosteroids and 
calcineurin inhibitors could ameliorate the clinical manifestation of AD. AD is frequently 
the first clinical manifestation of atopic disease in infancy. Basic therapy of AD comprises 
optimal skin care, emollient creams, topical corticosteroids and/or topical calcineurin 
inhibitors. Despite a strong rationale, hyposensitization with specific immunotherapy is 
not an established strategic treatment of AD. However, a recent study has shown that 
SCIT with HDM allergen extracts in adults AD patients with positive skin test toward 
HDM allergens is effective in reducing the SCORAD index and reducing, in the mean 
time, the need for topical corticosteroids. A wide clinical use of SCIT is, however, limited 
by the inconvenience and safety profile of this route of administration. A sublingual route 
has emerged as an effective alternative to subcutaneous immunotherapy. A recent trial, 
performed in children with AD, has shown that SLIT with HDM extracts could be 
effective in mild and moderate disease. SIT could be an effective and causal treatment of 
atopic dermatitis in patients with aeroallergen sensitivity. SLIT can modulate the 
immuno-system in patients with AD and HDM sensitivity. Several clinical trials (both 
controlled or uncontrolled) have shown that SIT is able to reduce the SCORAD and to 
reduce the use of symptomatic topical products. In conclusion the data available from 
different trials suggest that SIT (both SCIT and SLIT) could be a relevant therapeutic 
option in the management of AD. 
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